We study cartels that operated in the US generic drug industry, leveraging quarterly Medicaid data from 2011-2018 and a difference-in-differences approach comparing the evolution of prices of allegedly collusive drugs with a group of competitive control drugs. Our analysis highlights (i) the...

Abstract: This article discusses the prosecution of excessive pricing cases regarding pharmaceutical products under EU law in its regulatory context. In recent years the legal framework for the pursuit of such cases, based on the United Brands precedent, has been established more firmly. The...